COMPANY:

NGeneBio

"NGeneBio...launched MRDaccuPanel AML FLT3, an NGS-based ultra-sensitive gene diagnostics product to assist in the prescription of targeted therapies, monitor treatment, and predict relapse in acute myeloid leukemia (AML) patients."

"NGenBio...announced on the 26th that it has successfully launched its automated genome analysis software, NGeneAnalySys™ (NGAS), for the first time in Romania."

"Engenbio...announced on the 22nd that it will acquire 'TOPLAB', a CLIA lab located in New Jersey. This is the second acquisition of CLIA Lab, following the acquisition of CLIA Lab in California, USA last March."

"NGeneBio...announced on the 22nd that NGeneBioAI, an American corporation, will acquire the CLIA (laboratory standard certification) lab facility located in San Diego, USA. revealed...The CLIA Lab to be acquired this time is a facility established in 2022 by Vertis...and has acquired CLIA (Laboratory Standard Certification ) and CAP ( College of American Pathologists ) certification. The company explained that it will actively utilize the CLIA lab to discover new biomarkers and provide analysis services in the cancer and dementia fields in the United States in the future." "

"Engenbio...announced on the 13th that it has signed a business agreement with Genolution...Through this business collaboration, NGenBio plans to cooperate with Genolution in launching an expandable system to automate the entire NGS testing workflow, including nucleic acid extraction, library production, and data analysis steps."

"NGeneBio...has launched its automated cancer genome analysis software, NGeneAnalySys™ (NGAS), on -premise. On the 1st, they announced the global launch of a type solution and announced that they would expand into an AI- based customized disease solution business."

"Engenbio...announced on the 24th that it will supply a new blood cancer precision diagnosis product (HEMEaccuTest ™) to Seoul National University Hospital...The Him Accu Test is a product that additionally applies cancer genes to reflect the newly revised WHO (World Health Organization) blood cancer diagnosis guidelines. Unlike existing PCR testing methods, which require testing for each genetic mutation each time, NGS testing based on the Him Accu Test diagnostic kit can diagnose various genetic mutations related to blood cancer with a single test. The Power Accu Test has the advantage of providing customized treatment benefits to patients and providing various information to hospitals through a single test."

"Engenbio...Vertis...are working on AI early diagnosis based on Multi Omics. It was announced on the 10th that a business agreement was signed for technology development and commercialization...Through this business agreement, the two companies plan to establish a strategic partnership and promote commercialization related to the development of precise diagnosis and early diagnosis technology for high-risk diseases such as cancer and dementia . In particular, we plan to focus our capabilities on developing multi-omics-based AI diagnostic technology that combines the strengths of both companies: genomic data analysis and proteome data analysis technology."

"South Korean medical diagnostic company NGeneBio Co. announced on Friday that it has received approval for the sale of its in-vitro diagnostic medical device, 'SOLIDaccuTest DNA,' based on next-generation sequencing (NGS) technology from the Thailand Food and Drug Administration."

"NgeneBio, a Kosdaq-listed biotech firm, said Tuesday that it has obtained marketing authorization for Hemeaccutest, a blood cancer precision diagnostic panel based on next-generation sequencing (NGS) technology, from the Thai Food and Drug Administration (TFDA). Hemeaccutest, utilizing NGS, can identify mutations in over 100 genes associated with various hematological malignancies, such as myelodysplastic syndromes (MDS), myeloproliferative neoplasms (MPN), and lymphomas....NGeneBio is currently in the process of obtaining TFDA marketing authorization for other flagship products: Solidacutest, a precision diagnostic panel for solid tumors, and HlaacutestAll, a precision diagnostic panel for histocompatibility antigens."

"NGeneBio...announced the target of targeted therapy and immunotherapy in NGeneAnalySys, its next-generation sequencing technology-based cancer gene analysis software. It was announced on the 6th that it has launched a version with an added function that provides a cancer companion diagnosis report that can check biomarkers."

"NGenBio has developed 'ctDNAaccuPanel™ Lung', a lung cancer precision diagnosis technology that analyzes with high precision information on circulating tumor DNA (ctDNA) present in trace amounts in the blood using 'Liquid Biopsy' technology from the World Lung Cancer Association.' is scheduled to be presented."